| (Values in U.S. Thousands) | Jun, 2016 | Jun, 2015 | Jun, 2014 | Jun, 2013 | Jun, 2012 |
| Sales | 2,390 | 2,880 | 5,280 | 3,600 | 2,980 |
| Sales Growth | -17.01% | -45.45% | +46.67% | +20.81% | -16.53% |
| Net Income | -9,040 | -3,920 | -1,650 | -2,140 | -3,550 |
| Net Income Growth | -130.61% | -137.58% | +22.90% | +39.72% | +41.13% |
Progen Pharmaceuticals Ltd (PGLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Progen Pharmaceuticals Ltd was incorporated on 1989 under the laws of the Commonwealth of Australia and domiciled in the State of Queensland. The Company is a biotechnology company. It is engaged in the discovery, development and commercialization of small molecule therapeutics for the treatment of cancer. The Company operates the Research and Development business segment in Australia. The Company focuses on dual mechanism anti-angiogenesis and anti-metastatic oncology products, which control tumor size and spread. The Company is subject to various laws, regulations, policies, guidelines and recommendations relating to such matters as safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the protection of the environment. Furthermore, there has been a general trend towards greater regulation of the pharmaceutical industry and its products.